Teva Pharmaceutical Industries Ltd. (TEVA)

20.90
0.09 0.43
NYSE : Health Technology
Prev Close 20.81
Open 21.05
Day Low/High 20.75 / 21.10
52 Wk Low/High 10.85 / 37.94
Volume 14.77M
Avg Volume 22.51M
Exchange NYSE
Shares Outstanding 1.01B
Market Cap 19.12B
EPS -16.40
P/E Ratio N/A
Div & Yield 0.72 (3.74%)

Latest News

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

Dow Jumps Over 300 Points, Posting Its Fifth Straight Day of Gains

The Dow, S&P 500 and Nasdaq all finish higher on Thursday.

Stock Markets Around the World Are Soaring Again

Stock Markets Around the World Are Soaring Again

Japanese, Hong Kong and European markets continue Wednesday's Wall Street rally.

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

GM, Teva, Facebook and Other New Jana Partners Positions

GM, Teva, Facebook and Other New Jana Partners Positions

The insurgent manager that helped engineer the Amazon-Whole Foods combination just offered up a window into his latest allocations, any of which could soon become campaigns. Both Jana Partners and Warren Buffett's Berkshire Hathaway Inc. reported new positions in Teva

Teva Shares Pop After-Hours on News of Berkshire Investment

Teva Shares Pop After-Hours on News of Berkshire Investment

Berkshire Hathaway purchased 18.9 million shares of the drugmaker, according to its 13F filing.

Clearly, Warren Buffett Loves Apple's Stock

Clearly, Warren Buffett Loves Apple's Stock

Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Stocks ended higher on Tuesday.

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?

QVAR® RediHaler™ Product Image (Photo: Business Wire)

QVAR® RediHaler™ Product Image (Photo: Business Wire)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that QVAR ® RediHaler ™ (beclomethasone dipropionate HFA) Inhalation Aerosol is now commercially available to patients in both 40 mcg and...

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.

Teva Announces Launch Of A Generic Version Of Syprine® In The United States

Teva Announces Launch Of A Generic Version Of Syprine® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic version of Syprine ®1 (trientine hydrochloride) capsules, 250 mg, in the U.

Teva Shares Tank On Weak Outlook

Teva Shares Tank On Weak Outlook

The Israel-based drug maker reported fourth-quarter numbers that topped analysts' expectations, but its outlook came in below estimates.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

The free market is going to take back control of interest rates.

Teva Reports 2017 Full Year And Fourth Quarter Financial Results

Teva Reports 2017 Full Year And Fourth Quarter Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the quarter ended December 31, 2017.

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

The stock market continues to be under considerable pressure. Here is one thing not to do right now amidst the carnage.

Investors Learned One Valuable Lesson Watching the Dow's 1,175-Point Crash

Investors Learned One Valuable Lesson Watching the Dow's 1,175-Point Crash

The Dow Jones Industrial Average blew up on Monday, plain and simple. Here is one lesson investors should have learned.

European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application

European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin...

Teva Completes Amendment To Credit Facilities

Teva Completes Amendment To Credit Facilities

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its financial leverage ratio...

Teva Announces Completion Of Global Women's Health Divestiture To CVC Capital Partners

Teva Announces Completion Of Global Women's Health Divestiture To CVC Capital Partners

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of a portfolio of products within its global women's health business across contraception, fertility, menopause and...

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2017 Financial Results At 8 A.m. ET On February 8, 2018

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2017 Financial Results At 8 A.m. ET On February 8, 2018

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2017 financial results on Thursday, February 8, 2018 at 7:00 a.

NYC Joins Cities, Counties and States In Bringing Opioid Lawsuit

NYC Joins Cities, Counties and States In Bringing Opioid Lawsuit

New York City sues Purdue Pharma, Teva Pharmaceutical, Allergan, Johnson and Johnson, Endo International, McKesson, AmerisourceBergen and Cardinal Health over how opioids have devastated the city and its services.

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Are Politics and Proxy Firms Hurting Your Investment Returns?

Stick to the fundamentals when making investment decisions.

Teva Announces Top-Line Results From Phase III Studies Of Subcutaneously Administered Reslizumab In Patients With Severe Eosinophilic Asthma

Teva Announces Top-Line Results From Phase III Studies Of Subcutaneously Administered Reslizumab In Patients With Severe Eosinophilic Asthma

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that a Phase III registration study evaluating subcutaneously administered reslizumab (110 mg) in a pre-filled syringe did not meet its primary...

Opioids Get Their Day In Washington, but Effort To Dump Medicaid Gets Spotlight

Opioids Get Their Day In Washington, but Effort To Dump Medicaid Gets Spotlight

As opioid crisis becomes more deadly, public hearings put the pain killers front and center. But in bitterly divided Washington one meeting is more about chopping Medicaid.

TheStreet Quant Rating: D+ (Sell)